Question 69

Mycophenolate is subject to a Risk Evaluation and Mitigation Strategy (REMS) program because current patients should avoid becoming pregnant.

Mycophenolate is a medication that has been identified as having significant risks during pregnancy, necessitating a REMS program to help prevent fetal exposure. The REMS program is designed to inform patients and healthcare providers about these risks and to promote safe use.

A) Sertraline

Sertraline is an antidepressant that is not specifically subject to a REMS program for pregnancy-related risks. While caution is advised when prescribing sertraline during pregnancy, it does not have the same level of risk associated with fetal harm that would warrant a REMS.

B) Ondansetron

Ondansetron is an antiemetic used primarily for nausea and vomiting. Although its safety during pregnancy has been debated, it is not associated with the same level of concern as mycophenolate, and thus it is not under a REMS program related to pregnancy.

C) Montelukast

Montelukast is a leukotriene receptor antagonist used for asthma and allergies. It does have some considerations for use during pregnancy, but it does not require a REMS program, as the risks associated with its use in pregnant patients are not as severe as those associated with mycophenolate.

D) Mycophenolate

Mycophenolate is a powerful immunosuppressant that is known to cause significant birth defects and miscarriage if used during pregnancy. Therefore, it is subject to a REMS program to ensure that patients are adequately informed of the risks and to prevent pregnancy during treatment.

Conclusion

Mycophenolate is the only medication on this list that is specifically governed by a REMS program due to its serious risks in pregnancy. The other options, while they may require caution in certain situations, do not have the same level of risk that necessitates such a program. This distinction emphasizes the critical importance of careful medication management in individuals of childbearing potential.